How is IGF-1 DES dosed and mixed?

Every vial at a glance.

Concentration is the vial's amount over its water; units are the dose over the concentration, times 100, on a U-100 syringe.
Vial1 mL of water2 mL of water
1 mg1 mg/mL: 100 mcg is 10 units, 200 mcg is 20 units0.5 mg/mL: 100 mcg is 20 units, 200 mcg is 40 units
2 mg2 mg/mL: 100 mcg is 5 units, 200 mcg is 10 units1 mg/mL: 100 mcg is 10 units, 200 mcg is 20 units

Jump to a vial 1 mg 2 mg

Searches found no label or human trial giving an IGF-1 DES dose; the Increlex label (mecasermin, a different product) gives a starting dose of 0.04 mg/kg to 0.08 mg/kg twice daily for growth failure in children 2 years of age and older with severe primary IGF-1 deficiency or GH gene deletion with neutralizing antibodies to GH.1

Supply, mixing and syringe units

Searches of DailyMed and PubMed found no label or maker's leaflet giving IGF-1 DES vial strengths or a mixing method, and no human dose, so the vial amounts, water volumes and doses in the table above are arithmetic examples only, not a product strength or a sourced dose. Increlex is mecasermin, a recombinant human IGF-1 of 70 amino acids, supplied as a ready solution, 40 mg/4 mL (10 mg/mL) in a multiple-dose vial, and its label describes no powder or water for mixing.1 Its label gives a formula for converting mg/kg doses to units on a syringe, using 1 mL/10 mg and 100 units/1 mL.1 Mixing a powder of any strength is covered in the mixing guide.

What IGF-1 DES is, and whether it has a label

IGF-1 DES is des(1-3)IGF-I, a variant of human IGF-I that lacks the tripeptide Gly-Pro-Glu at the N-terminus.2 A 1996 review by Ballard and colleagues describes it as generally about 10-fold more potent than IGF-I at stimulating cultured cells, says the increased potency is retained in part when it is given in vivo, and says clinical uses had not yet been evaluated.2 A 2021 anti-doping paper by Mongongu and colleagues states that IGF-I analogues including this one were never approved for use in humans and are readily available as black market products for bodybuilding.3 A DailyMed search for the name found no label.

Rat studies hold the only dose figures found for this variant: and none is a human dose: Martin and colleagues (1991) gave 0.9 mg/kg a day for 7 days by osmotic minipump to young male rats with reduced kidney mass, beside IGF-I at 0.9 and 2.2 mg.kg body wt-1.day-1, and Tomas and colleagues (1991) infused 1.08 mg/kg a day over 7 days in streptozotocin-induced diabetic rats.45

Dose and schedule

Searches of ClinicalTrials.gov and PubMed found no human dosing trial of IGF-1 DES, so no trial arm can be listed.

The Increlex label (mecasermin, a different product), for growth failure in children 2 years of age and older with severe primary IGF-1 deficiency or GH gene deletion with neutralizing antibodies to GH, says the dose is individualized for each patient and gives a starting dose of 0.04 mg/kg to 0.08 mg/kg twice daily by subcutaneous injection.1 It steps by 0.04 mg/kg per dose after at least one week if well tolerated, up to a maximum of 0.12 mg/kg twice daily in children with severe primary IGF-1 deficiency.1 Its five clinical studies (four open-label and one double-blind, placebo-controlled) gave subcutaneous doses generally ranging from 0.06 to 0.12 mg/kg twice daily in 71 children with severe primary IGF-1 deficiency, treated for a mean duration of 3.9 years.1

Storage

Searches found no storage or stability data for IGF-1 DES before or after mixing. The Increlex label says its solution vials are stable when refrigerated at 2º to 8ºC (36º to 46ºF) before opening, and for 30 days after initial vial entry when stored refrigerated at 2º to 8ºC, with freezing avoided and the vials protected from direct light.1

Safety statements on the Increlex label

The Increlex label warns of severe hypoglycemia and says to dose shortly before or after a meal or snack.1 It reports several cases of malignant neoplasia in children treated, and says it is contraindicated in children with malignant neoplasia or a history of malignancy.1 It says safety and effectiveness have not been established in children below 2 years of age or in patients aged 65 and over.1

Frequently asked questions

What route do labels give for IGF-1 DES?

Searches found no IGF-1 DES label or human trial that states a route. The Increlex label gives the subcutaneous route, not intravenous, with sites to rotate.1

References

  1. DailyMed. These highlights do not include all the information needed to use INCRELEX ® safely and effectively. See full prescribing information for INCRELEX ® . INCRELEX ® (mecasermin) injection, for subcutaneous use Initial U.S. Approval: 2005. 2025. dailymed.nlm.nih.gov
  2. PubMed. Des(1-3)IGF-I: a truncated form of insulin-like growth factor-I. 1996. pubmed.ncbi.nlm.nih.gov
  3. PubMed. Detection of LongR3 -IGF-I, Des(1-3)-IGF-I, and R3 -IGF-I using immunopurification and high resolution mass spectrometry for antidoping purposes. 2021. pubmed.ncbi.nlm.nih.gov
  4. PubMed. IGF-I and its variant, des-(1-3)IGF-I, enhance growth in rats with reduced renal mass. 1991. pubmed.ncbi.nlm.nih.gov
  5. PMC. Increased weight gain, nitrogen retention and muscle protein synthesis following treatment of diabetic rats with insulin-like growth factor (IGF)-I and des(1-3)IGF-I. pmc.ncbi.nlm.nih.gov